ArticleCost effectiveness and resource allocation : C/E2023

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis.

Peng-Fei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.